NCT03724240View on ClinicalTrials.gov

Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

PHASE3UnknownINTERVENTIONAL

Enrollment

624

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

September 30, 2019

Study Completion Date

December 31, 2019

Conditions

Hay Fever

Interventions

BIOLOGICAL

Placebo solution

4 x 2 injection over 21 days the dosage is100 µg/ml

BIOLOGICAL

gpASIT+TM

4 x 2 injection over 21 days the dosage is100 µg/ml

Sponsors

Lead Sponsor

ASIT Biotech S.A.

All Listed Sponsors

lead

ASIT Biotech S.A.

INDUSTRY

NCT03724240 - Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter